Application
Western Blot analysis of PCAF expression in transfected 293T cell line by PCAF monoclonal antibody (M02), clone 1H2.Lane 1: PCAF transfected lysate(93 KDa).Lane 2: Non-transfected lysate.Application
Western blot analysis of PCAF over-expressed 293 cell line, cotransfected with PCAF Validated Chimera RNAi ( Cat # H00008850-R01V ) (Lane 2) or non-transfected control (Lane 1). Blot probed with PCAF monoclonal antibody (M02), clone 1H2 (Cat # AT3205a ). GAPDH ( 36.1 kDa ) used as specificity and loading control.| Product Name | PCAF Antibody (monoclonal) (M02) |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | CAF, GCN5, GCN5L, GCN5L1, P/CAFp300/CBP-associated factor |
| Clonality | Monoclonal |
|---|---|
| Isotype | IgG2a |
| Clone Number | 1H2 |
| Host Species | Mouse |
| Tested Applications | WB |
| WB:1:500~1000 |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Alternative Names | CAF GCN5 GCN5L GCN5L1 P/CAFp300/CBP-associated factor |
|---|---|
| Molecular Weight(MW) | 93013 Da |
| Tissue Specificity | PCAF (AAH60823, 353 a.a. ~ 452 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. |
| Entrez Gene | 8850 |
|---|
Application
Western Blot analysis of PCAF expression in transfected 293T cell line by PCAF monoclonal antibody (M02), clone 1H2.Lane 1: PCAF transfected lysate(93 KDa).Lane 2: Non-transfected lysate.
Application
Western blot analysis of PCAF over-expressed 293 cell line, cotransfected with PCAF Validated Chimera RNAi ( Cat # H00008850-R01V ) (Lane 2) or non-transfected control (Lane 1). Blot probed with PCAF monoclonal antibody (M02), clone 1H2 (Cat # AT3205a ). GAPDH ( 36.1 kDa ) used as specificity and loading control.| Application Notes | WB:1:500~1000 |
|---|
| Form | Liquid |
|---|---|
| Storage Instructions | For short-term storage, store at 4° C. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles. |
| Storage Buffer | Clear, colorless solution in phosphate buffered saline, pH 7.2 . |
